Nura Bio announces phase 1 study for oral, brain-penetrant SARM1 inhibitor
Click Here to Manage Email Alerts
A Bay Area-based biopharmaceutical company has announced initiation of a phase 1 clinical trial for its oral, small molecule SARM1 inhibitor, NB-4746, to treat a wide range of conditions affecting the central, peripheral and ocular nervous systems.
According to a press release from Nura Bio, the randomized, double-blind, placebo-controlled, single ascending and multiple ascending dose trial will assess safety, tolerability and pharmacokinetics of NB-4746 in healthy volunteers.
NB-4746 was shown to offer structural and functional protection in preclinical disease models including amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury and chemotherapy-induced peripheral neuropathy, the company stated.
In preclinical models, according to Nura, NB-4746 significantly reduced, and in some cases prevented, increases of telltale biomarker neurofilament light.
“We are excited about the potential of NB-4746,” David Lau, PhD, senior vice president of development sciences at Nura Bio, said in the release. “We expect to enter clinical trials in a patient population in 2024, to evaluate the impact of NB-4746 on axonal injury and neurofilament light levels.”